Replies to post #257176 on Biotech Values

[DewDiligence]

PULM reverse-merges with—(private)—Eos Senolytix:

https://www.prnewswire.com/news-releases/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan-302726133.html

Following the closing of the proposed Merger…the pre-Merger Pulmatrix stockholders are expected to own approximately 6% of the combined company, while pre-Merger Eos stockholders, including investors participating in the Financings…are expected to own approximately 94%
.
Upon completion of the Merger, the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker symbol "EOSX."

… Eos SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging.

In this transaction, PULM is getting compensation for its Nasdaq listing, period.

PULM is itself the (failed) product of a 2015 reverse-merger (#msg-114559267).